{"id":"pizotifen","rwe":[],"tags":[{"label":"pizotifen","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"5-hydroxytryptamine receptor 2C","category":"target"},{"label":"HTR2C","category":"gene"},{"label":"HTR2B","category":"gene"},{"label":"CHRM1","category":"gene"},{"label":"N02CX01","category":"atc"},{"label":"Active","category":"status"},{"label":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","category":"company"},{"label":"Analgesics","category":"pharmacology"},{"label":"Analgesics, Non-Narcotic","category":"pharmacology"},{"label":"Antidepressive Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Psychotropic Drugs","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"},{"label":"Serotonin Agents","category":"pharmacology"},{"label":"Serotonin Antagonists","category":"pharmacology"}],"phase":"phase_2","safety":{"safetySignals":[{"llr":82.342,"date":"","count":11,"signal":"Vestibular migraine","source":"DrugCentral FAERS","actionTaken":"Reported 11 times (LLR=82)"},{"llr":67.151,"date":"","count":15,"signal":"Clonus","source":"DrugCentral FAERS","actionTaken":"Reported 15 times (LLR=67)"},{"llr":64.343,"date":"","count":15,"signal":"Hyperreflexia","source":"DrugCentral FAERS","actionTaken":"Reported 15 times (LLR=64)"},{"llr":61.79,"date":"","count":11,"signal":"Therapeutic response changed","source":"DrugCentral FAERS","actionTaken":"Reported 11 times (LLR=62)"},{"llr":55.617,"date":"","count":11,"signal":"Endometrial cancer","source":"DrugCentral FAERS","actionTaken":"Reported 11 times (LLR=56)"},{"llr":46.587,"date":"","count":15,"signal":"Muscle twitching","source":"DrugCentral FAERS","actionTaken":"Reported 15 times (LLR=47)"}],"commonSideEffects":[{"effect":"Vestibular migraine","drugRate":"LLR 82","severity":"common"},{"effect":"Clonus","drugRate":"LLR 67","severity":"common"},{"effect":"Hyperreflexia","drugRate":"LLR 64","severity":"common"},{"effect":"Therapeutic response changed","drugRate":"LLR 62","severity":"common"},{"effect":"Endometrial cancer","drugRate":"LLR 56","severity":"common"},{"effect":"Muscle twitching","drugRate":"LLR 47","severity":"common"}]},"trials":[],"aliases":[],"company":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","patents":[],"pricing":[],"allNames":"pizotyline","offLabel":[],"synonyms":["pizotyline","pizotifen","pizotifen malate"],"timeline":[],"approvals":[],"brandName":"Pizotyline","ecosystem":[],"mechanism":{"target":"5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B","targets":[{"gene":"HTR2C","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2C","protein":"5-hydroxytryptamine receptor 2C"},{"gene":"HTR2B","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2B","protein":"5-hydroxytryptamine receptor 2B"},{"gene":"CHRM1","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M1","protein":"Muscarinic acetylcholine receptor M1"},{"gene":"DRD2","source":"DrugCentral","target":"D(2) dopamine receptor","protein":"D(2) dopamine receptor"},{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"},{"gene":"HTR7","source":"DrugCentral","target":"5-hydroxytryptamine receptor 7","protein":"5-hydroxytryptamine receptor 7"},{"gene":"HTR1A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1A","protein":"5-hydroxytryptamine receptor 1A"}],"modality":"Small Molecule","drugClass":"pizotifen","explanation":"Imagine your brain has a messaging system that uses serotonin as a key player. Pizotyline blocks one of the receptors that serotonin attaches to, which can help regulate the flow of serotonin signals and potentially treat conditions related to serotonin imbalance.","oneSentence":"Pizotyline works by binding to and blocking the 5-hydroxytryptamine receptor 2C, which is involved in serotonin signaling.","technicalDetail":"Pizotyline acts as a selective antagonist at the 5-HT2C receptor, which is a subtype of serotonin receptor involved in various physiological processes, including mood regulation, appetite, and sleep."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2220","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=Pizotifen","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pizotifen","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:26:07.379891","biosimilars":[],"competitors":[{"drugName":"clonidine","drugSlug":"clonidine","fdaApproval":"1974-09-03","patentExpiry":"Sep 8, 2031","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"pizotifen","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"clonidine","brandName":"clonidine","genericName":"clonidine","approvalYear":"1974","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06500624","phase":"NA","title":"Comparative Efficacy of Escitalopram Monotherapy and Escitalopram in Adjuvant With Pizotifen in Depressive Disorder","status":"COMPLETED","sponsor":"Riphah International University","startDate":"2024-06-03","conditions":["Depression"],"enrollment":88,"completionDate":"2024-09-30"},{"nctId":"NCT06158230","phase":"PHASE2","title":"Comparison of Efficacy Between Combination of Amitriptyline-propranolol and Pizotifen for Migraine Prophylaxis.","status":"UNKNOWN","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-03-19","conditions":["Migraine"],"enrollment":140,"completionDate":"2024-01-15"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NUI":"N0000167169","NDDF":"003497","UNII":"0BY8440V3N","CHEBI":"CHEBI:50212","INN_ID":"2693","RXNORM":"8373","UMLSCUI":"C0032036","ChEMBL_ID":"CHEMBL294951","KEGG_DRUG":"D05523","DRUGBANK_ID":"DB06153","PUBCHEM_CID":"27400","SNOMEDCT_US":"349963006","IUPHAR_LIGAND_ID":"93","MESH_DESCRIPTOR_UI":"D010918"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"78%"},"publicationCount":318,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"N02CX01","allCodes":["N02CX01"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","companyId":"bangabandhu-sheikh-mujib-medical-university-dhaka-bangladesh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pizotyline, also known as Pizotifen, is a small molecule drug that targets the 5-hydroxytryptamine receptor 2C. It is developed and owned by Bangabandhu Sheikh Mujib Medical University in Bangladesh. The exact indications and commercial status of Pizotyline are unknown. As a pizotifen drug, it is likely used to treat conditions related to serotonin receptor modulation. Further research is needed to determine its safety profile and potential side effects.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}